1-3 of 3
Gordon Royle
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Is initial treatment with dasatinib for newly diagnosed chronic Phase chronic myeloid leukemia, followed by switching to imatinib for those that achieve MR3.0 at 12 months, an effective strategy? Results of the Phase 2 kinase inhibition with sprycel startup study

Free
Peter Browett, Zhenqiang Wu, Humphrey Pullon, Jenny Yoon, Melissa Firth, Shani Peleg, Emma-Jane McDonald, Sarah Benge, Bart Baker, Merit Hanna, Victoria Campion, Shahidul Islam, Gordon Royle, Nicky Lawrence, Katrina Sharples, Lucy Pemberton
Journal: Blood
Blood (2025) 146 (Supplement 1): 2006.
https://doi.org/10.1182/blood-2025-2006
Published: 2025
Journal Articles

Antibodies Targeting Subunit 1 of the N -Methyl-D-Aspartate Receptor May Contribute to Immune Mediated Thrombocytopenia.

Free
Maggie L. Kalev-Zylinska, MD, PhD, FRCPA, Hilary A. Blacklock, Gordon Royle, Ross Henderson, Peter Flanagan, Sharon Jackson, Isuru Dilshan, Wymond Symes, Kathryn Goldstone, Peter Browett, Matthew J. During
Journal: Blood
Blood (2007) 110 (11): 2110.
https://doi.org/10.1182/blood.V110.11.2110.2110
Published: 2007
Journal Articles

Inactivation of the Fanconi Anemia Group C Gene Augments Interferon-γ–Induced Apoptotic Responses in Hematopoietic Cells

Free
R. Keaney Rathbun, Gregory R. Faulkner, Marika H. Ostroski, Tracy A. Christianson, Grant Hughes, Gary Jones, Robert Cahn, Richard Maziarz, Gordon Royle, Winifred Keeble, Michael C. Heinrich, Markus Grompe, Paula A. Tower, Grover C. Bagby
Journal: Blood
Blood (1997) 90 (3): 974–985.
https://doi.org/10.1182/blood.V90.3.974
Published: 1997